Sangamo BioSciences Announces Presentation of Clinical Data from ZFP Therapeutic® for HIV/AIDS at ICAAC 2012

Sangamo BioSciences, Inc. SGMO announced that data from its Phase 1 clinical programs to develop SB-728-T, a novel therapeutic approach designed to generate a "functional cure" for  HIV/AIDS, were presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). The meeting is being held in San Francisco from September 9-12, 2012.  "The immunologic data presented at ICAAC have predictive implications for the success of this exciting new therapeutic approach to HIV and the realization of a 'functional cure' for the disease," commented Rafick-Pierre Sékaly,  Ph.D., Co-Director & Chief Scientific Officer, the Vaccine & Gene Therapy Institute of Florida (VGTI Florida), whose laboratory carried out the analysis.  "SB-728-T treatment results in an unprecedented and durable increase in CD4+ cells.  Importantly, our analysis shows that this is primarily due to the expansion of CD4+ T-cell types that are vital for the successful reconstitution of the immune system in HIV-infected individuals - the central and transitional memory cells." "These data are very important because CD4 T-cells, especially memory T-cells, are precisely the cell type that we would want See full press release